RightFit
RecruitingPhase not listed

Machine Learning Approaches to Personalized Therapy for Advanced Non-small Cell Lung Cancer With Real-World Data

Who can join

As published by the study on ClinicalTrials.gov. "Not stated" means the study hasn't said — ask the study team.

Age
No age limits stated
Sex
All sexes
Healthy volunteers
Not accepted
Compensation
Not stated

Other requirements are listed under Eligibility below. Only the study team can confirm whether you can join.

What to expect

No one can promise a trial will help you personally — that is what the research is trying to find out.

What participation involves

Not stated in the study description — ask the study team about visits and procedures.

Compensation
Not stated
  • Study-related exams and procedures are typically provided at no cost. This is how many trials work in general — confirm the details for this study with the study team.
  • Participants are monitored closely by the research team throughout the study.
  • Some participants may receive access to an investigational treatment, which is still being studied.
  • Your participation helps researchers learn whether this approach could help future patients.

About this study

This research will leverage machine learning (ML) and causal inference techniques applied to real-world data (RWD) to generate evidence that personalizes treatment strategies for patients with advanced non-small cell lung cancer (aNSCLC). Rather than influencing regulatory decisions or clinical guidelines, the goal of this trial is to refine treatment selection among existing therapeutic options, ensuring that care is tailored to individual patient characteristics. Additionally, by generating real-world evidence, these findings will inform the design and implementation of future clinical trials. Importantly, the methodological advancements will establish a pipeline that extends beyond aNSCLC, facilitating the identification of optimal dynamic treatment regimes (DTRs) for other complex diseases.

Compensation is read from the study's own description and may be missing — always confirm with the study team.

Eligibility

Official eligibility criteria

Inclusion Criteria Subjects must meet all of the following eligibility criteria: * Diagnosed with advanced NSCLC between January 1, 2011, and June 30, 2024. * Follow-up available until December 31, 2024, with a minimum potential follow-up period of at least six months. Exclusion Criteria Subjects meeting any of the following criteria at baseline will be excluded: * Fewer than one day of follow-up post-initiation of first-line (1L) therapy. * Presence of a targetable mutation, including ALK, BRAF, EGFR, KRAS, or ROS1. * PD-L1 expression \<50% at baseline (restricted to patients with PD-L1 ≥50%). * First-line treatment limited to immunotherapy or chemoimmunotherapy (excluding other treatment regimens). * Patients receiving second-line (2L) treatment, including those enrolled in a clinical study.

Study sites (1)

UT